| ￥5800 | |
| Z04566-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized NKG2A&CD94[Biotin], His & Avi & Flag, Human at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate can bind AntiNKG2A Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 17.9 kDa (CD94)&18.3 kDa (NKG2A) | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 33-48 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies. |
| Synonyms | CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
